TNBC (n=74)HR+ (n=205)

Infer

red a

ctivit

ySi

gnific

ance

[-log 1

0(p)]

p=0.05

Infer

red a

ctivit

y G1-2 (n=117)G3 (n=162)

Sign

ifican

ce[-lo

g 10(p

)]Si

gnific

ance

!"#$%

&'()*+

!"#$%&'

(%)*+

,-./0#01/,-./0#01/,-./0#01/,-./0#01/,-./0#01/

!"#$%&'!"#$%&'!"#$%&'!"#$%&'

p=0.05

(%

p=0.05

Corre

lation

[Spe

arma

n Rho

]

2#&$/3#45.67.%881&5)3599./%'&#01"5/.%&.5#"9:.;%';)"%/<.="5#/0.3#&35".>?@A."5B5#9/.39%&%3#99:)"595B#&0.5&"%3;85&0.67.%881&5./1=46419#0%6&/

,-./01$)-2.34521$&63,7.01283928:2.1;63<212.3=3>70?-/8%@63412)-283A285&63B7.01283C2D2.E63F783AGH?5/20I63=8H.27034?-822J2/00K63L#M7.341/?:2#2.N6347D/8234?-M71#$?-O63,-./01/783F7?:/0?-P63Q-$M703B7.8&'63R7803<212.34/88&&63S71-/703C7.M&;63S7./$83T783S7?:2#28D2.%-&@634-7-.$$53U7D/57H2-&63,-./01/7834?-2M&E63L.8013R2/8MV##2.&I63W$#:M7.3SX##2.&K63>.2H2./:3S7.MY&N63<71./?:34$$8"4-/$8%&63W7#281/873Z2:#[GH$T7E63S/?-72#3\81?-&O634/D]##23^$/D#E

&_MMG8/1]A/$3^^,63,G#T2.3,/1]63,=63\4=63;_801/1G13`X.3<71-$#$%/263<-/#/))0"\8/T2.0/1a13S7.DG.%63b2.M78]63@92)7.1M2813$` b]82?$#$%] 78H cD0121./?063\8/T2.0/1]3R$0)/17#3L.#78%2863b2.M78]63EbAb3U2027.?-3bMDR63Z2G"_028DG.%63b2.M78]63I_801/1G123$`3<71-$#$%]63\8/T2.0/1]3R$0)/17#63R2/H2#D2.%63b2.M78]6KZ71/$87#3,2812.3`$.3QGM$.39/027020639B>d63R2/H2#D2.%3\8/T2.0/1]3R$0)/17#63b2.M78]63N92)7.1M2813$`3b]82?$#$%]378H3cD0121./?063\8/T2.0/1]3R$0)/17#63UCQR3=7?-2863b2.M78]63OA.27013,78?2.3,2812.63L#/07D21-"B.78:28-7G03B7002#63b2.M78]63P92)7.1M2813$`3b]82?$#$%]378H3cD0121./?06347873B#/8/:GM c``28D7?-63b2.M78]63&'B#/8/:3`X.3>.7G28-2/#:G8H23G8H3b2DG.10-/#`263\8/T2.0/1a10:#/8/:GM3>.78:`G.163b2.M78]63&&9/T/0/$83$`3b]82?$)71-$#$%]63_801/1G123`$.3<71-$#$%]63\8/T2.0/1]3R$0)/17#3R2/H2#D2.%63b2.M78]63&;B#/8/:283H2.3417H13BV#83bMDR63b2.M78]63@\8/T2.0/1a10:#/8/:GM34?-#20J/%"R$#012/863B#/8/:3`X.3b]8a:$#$%/23G8H3b2DG.10-/#`263B/2#63b2.M78]6

&ES7MM75281.GM3R7MDG.%63R$0)/17#3F2.G07#2M63R7MDG.%63b2.M78]6&I_801/1G123$` <71-$#$%]63<71-$#$%/23Z$.H-2002863B7002#63b2.M78]63&K92)7.1M2813$` b]82?$#$%] 78H cD0121./?063\8/T2.0/1a10:#/8/:GM3R7MDG.%"L))28H$.`63b2.M78]63&N92)7.1M2813$`3b]82?$#$%]378H3cD0121./?063\8/T2.0/1]3R$0)/17#3S788-2/M63b2.M78]63&OR2#/$03B#/8/:GM3A2.#/8"AG?-63A2.#/863b2.M78]

_MMG8$0G.T2/##78?2 0G)).200/$86 2T70/$86 $. 7T$/H78?26 -702M2.%2H 70 7 :2] 17.%217D#2 -7##M7.: $` ?78?2.6 H./T28 D] 2e%e?-2?:)$/81 2f).200/$86 Q"?2## 2f-7G01/$86 78H/MMG8$0G)).200/T2 1GM$. M/?.$28T/.$8M281 (QSL*e S78] $`1-202 ).$?20020 %282.712 H2`/82H ?$MD/871/$80 $` /MMG82"?2## /8`/#1.7120 71 1-2 1GM$. 0/126 J-/?- ?78 D2 H212?12H D]/MMG8$-/01$?-2M/01.] (_R,*6 ,]Qc>6 $. M$.2 .2?281#] ?78 D2/8`2..2H `.$M %282"2f).200/$8 H2?$8T$#G1/$8e C-/#2 0/%8/`/?781J$.: -70 D228 H$82 1$ 01GH] %282 0/%871G.20 /8 1-2 QSL6 1-2?#/8/?7# .2#2T78?2 $` 0G?- /MMG82"?2## %282 0/%871G.2 $81-2.7)] -70 8$1 D228 01GH/2H 1$ 7 %.271 2f1281eC5 %&B5/0%'#05 0;5 ;:460;5/%/ 0;#0 0;5 %&$%B%$1#9 4#005"&/67 %881&5)3599 /%'&#01"5/ $505"8%&5 0;5 39%&%3#9 =5;#B%6"67 ?@D %& 4#"0%319#" "5/46&/5 06 &56#$E1B#&03;5860;5"#4:F

Q-/03).2028171/$83/031-23/812##2?1G7#3).$)2.1]3$`31-237G1-$.g).202812.e3,$817?131-2M3713?-./01$)-2.e0521$h/MMG8/1]D/$e?$M3`$.3)2.M/00/$831$3.2)./81378Hg$.3H/01./DG12e3

G*)HI)IJ

<.202812H371i34783=81$8/$3A.27013,78?2.34]M)$0/GMj6392?2MD2.3&'"&E63;'&P

?#3<'"61&$.. -5/190/

C2 )2.`$.M2H 7 .21.$0)2?1/T2").$0)2?1/T2 787#]0/0 $` 70GD021 $` 1-2 RLU;"82%71/T2 0GD)$)G#71/$8 J/1-/8 1-2b2)7.42)1$ 01GH] (Z,Q'&IO@E;K* /8 J-/?- J$M28 J/1-)./M7.] /8T70/T2 A, J2.2 .78H$M/52H 1$ 2/1-2. 87D")7?#/17f2#$. 0$#T281"D702H )7?#/17f2# `$##$J2H D] L, !&+e;NP RLU;"82%71/T2 )71/2810 J/1- 0G``/?/281 kG7#/1] 07M)#2.2M7/8/8% 1$ )2.`$.M J-$#2"1.780?./)1$M2 UZ=02k (l;''f&'K.27H0 )2. 1GM$.*e_MMG82 7?1/T/1] /8 1-2 QSL J70 /8`2..2H D] ?$M)7./8%2f).200/$8 $` ;@ /MMG82"?2##"0)2?/`/? %282 0/%871G.20H2./T2H D] A/8H27 21 7#e !;+ 1$ 1-$02 `.$M 7 D7?:%.$G8H)$)G#71/$8 $` &EKN 0/M/#7.#]").$`/#2H G802#2?12H 1GM$.07M)#20 `.$M 1-2 Z781cM/?0 H717D702e

K%'1"5.HF..-LM)/5N =#/5$.%881&5.$536&B6910%6&

&e \81?-63S/?-72#632137#e3Z7D")7?#/17f2#3T2.0G030$#T281"D702H3)7?#/17f2#3/8382$7H[GT7813?-2M$1-2.7)]3`$.327.#]3D.27013?78?2.3(b2)7.42)1$"bAb3KP*i373.78H$M/02H63)-7023@31./7#e3!"#$%&'(#$)* ;'&Km&Ni@EI"IK;e3

;e A/8H27 b63S#2?8/: A63Q$0$#/8/ S632137#i34)71/$12M)$.7#3H]87M/?03$`3/81.71GM$.7# /MMG823?2##03.2T27#31-23/MMG823#78H0?7)23/83-GM783?78?2.e3+,,-#.&/ ;'&@m@PiNO;"PI63

O50;6$/..

@6&391/%6&/

!"#

$%&' $()

*"+,%-

!./0+&

123(/3&4

$%)

$%56

$%57 $%8

+295

)!!+

132:

9&;4

$%)<

=$-/

$%5<

$/3)

=327

="&)(

!) "1+

/1+1

01!

>)&

$1"+0

$>$(

87+

1+5

=")8

"+=()

9.$*

/.+%

)/1+1

8="&

4+="&

4(+

(-($

!$"8

$>$"&5

.+3

9%$%

&3-

>95

+1.

%-$#

'26

3"(6

9/&

:/9'

?+#

15$$

()6@

/(&

"1#

23+1

$0$%

<+$%

<!3"15"7

7A..

9(3&

$%&8;

36A&

1+(9

!$")

3:1B

2$(&

A23);B

3->C&

.99

6%&

9"+)

78((

+%71

35$&

7A.!

=")&(

$$"&5

$$"&4

$$"))

$%);'

*/%&

&!&

$%&+

$%&!

$%&6

3&5+

&/?1&4

$$"&

6!=5

=%-&

"+.95

-+/5

="5(+

+9-6

$$"4

$%8<

$*=1&

$>$"B

.+(

$-./(&

$.+&

$1/7 #=1

./0+)

9(7)

19/+

!&$/35(

39()

..6

$$(5

="B(+

917%

()/.

9%5

1*!/&

!"#$%%&

'()$%%

*$%+$,"'"

#$%%&

'-.

'-/

'-.0

'1*

',$2

')3

'$3

#45"'()$%%

'26

78")$%%

78"#4

9:"

;,<2-=")$%%

78"#4

9:"

6<3")$%%

4# <4#

>4#

+4#

?.@?/

?>&=")$%%

7$A=,B+-<%&

CB&<DB+-<%&

?$3B,E"'")$%%& #E=B=BF<)"'")$%%&

!")$%%&

?E$%B<6"6$D6,<=<)")$%%&

!")$%%& '")$%%& 78")$%%& 4$D6,<=<)")$%%& ?>),B+->2$& G,>DA%B)E=$&

H6>+=<I$"<33AD$",$&+BD&$ JDD>=$"<33AD$",$&+BD&$

K=-$, #E=B=BF<)")$%%& K=-$,

;@3/MMG823?2##31])20

M

?

@

log2(

TPM+

1)

=*3Lf).200/$83$`3&'E3%282030)2?/`/? 1$3/MMG823?2##30GD)$)G#71/$803J2.23G02H31$3?.27123.2`2.28?23%282021H/01./DG1/$803703/83A*e3,*3_8`2..2H37?1/T/1]3(d"0?$.20*3/83n&;''3G802283?#/8/?7#3?7020e34/%8/`/?781#]3H/``2.281/7#37?1/T/1/203D21J2283D.2701378H3$1-2.31])203M7.:2H3J/1-3o378H3H/.2?1/$83$`301.$8%2.3700$?/71/$83/8H/?712H3/83?$#$.e3

=*3,#G012.2H3/MMG8237?1/T/1]30?$.203`$.3;NP3b2)7.42)1$ )71/2810e3A*3<.$)$.1/$803$`3b2)7.42)1$ )71/281031-713J2.23?$80/H2.2H3-/%-3(n&0H3`.$M3M278*638$.M7#3(J/1-/83&0H3$`3M278*6378H3#$J3(p"&0H3`.$M3M278*3`$.3/MMG8230GD021063?$M)7.2H31$3.2`2.28?23D.27013?78?2.307M)#20e

,$#H C7.MR$1

Infer

red

activ

ity sc

ore

@6"5.=%64/:

>=576"5/01$:.5&0":A M"8.M

M"8.?

-

P1"'5":

HQH HR.S55</ HR.S55</

<7?#/17f2#O'3M%gM;3J22:#]

Z7D")7?#/17f2#3&I'3M%gM;3J22:#]Q-23H$023J703.2HG?2H31$3&;I3M%gM;3

7`12.3.2?.G/1M2813$`3EKE3)71/2810

L)/.GD/?/83P'3M%gM;3

,]?#$)-$0)-7M/H2 K''3M%gM;

!54#"P5406 0"%#9.$5/%'&.67.,T-R)&5'#0%B5./500%&'Q

M ?

P01$:.U5/%'&

K%'1"5.VF.W881&5.46419#0%6&/.5&"%3;5$.S%0;%&.39%&%3#9.36B#"%#05/=?1/T/1/203(7D$T2*378H30/%8/`/?78?23(D2#$J*3`$.3.2?2)1$.30171G03(=*63%.7H23(A*378H31-237%%.200/T282003M7.:2.3B/KN3(,*e3^/8203H28$1/8%3&0H30-$J83J-2.237T7/#7D#2e3_830/%8/`/?78?23)#$1063?$#$.3/8H/?7120301.28%1-378H3H/.2?1/$83$`3700$?/71/$8e34/%8/`/?78?23)"T7#G203J2.23#/M/12H31$3'e'''&e

M

?

K%'1"5.JF.K699%319#".;5945".3599/.>XK,A.#"5.#//63%#05$.S%0;.$%775"5&0%#9./1"B%B#9=*3Q>R30?$.23J7030/%8/`/?781#]3).2H/?1/T23$83)7?#/17f2#"D702H3Qf `$.3c4639>46378H3),U /83MG#1/T7./7123M$H2#03A*3S$07/?3)#$130-$J/8%328./?-M2813$`3-/%-3Q>R30?$.23J/1-/83)71/281031-713-7H3),U ()q'e''&;*e

Model Endpoint odd ratio/hazard ratio(95 CI) p-value

Cox OS 0.55 (0.39-0.77) 0.0005Cox DFS 0.62 (0.47-0.81) 0.0004

Logistic regression pCR 1.63 (1.12-2.36) 0.0107

M ?

ImmunityBio

C;695)0"#&/3"%40685 /5N15&3%&' %& ="5#/0 3#&35" KKGT 36"5 =%64/%5/7"68 39%&%3#9 36;6"0/ 3#& =5 1/5$ 06 %$5&0%7: %881&5)3599 /%'&#01"5/FP453%7%3#99:D #$#40%B5 %881&%0: 0;"61'; L( "#0;5" 0;#& X)3599 "5/46&/5#445#"/ 4"5B#95&0 %& ;%';)"%/< XL?@F X;5 4#005"&/ 67 0;5/5 %881&5/%'&#01"5/D %& 4#"0%319#" 0;5 4"5/5&35 67 X 7699%319#" ;5945" 3599/D "5795300;5 39%&%3#9 =5;#B%6" 67 ="5#/0 3#&35" #&$ 8%';0 =5 1/5$ 06 %$5&0%7:0186"/ S%0; #& %&3"5#/5$ "5/46&/5 "#05 06 &56#$E1B#&0 3;5860;5"#4:F

-575"5&35/

r Z71G.7# :/##2. (ZB* ?2##0 (N&s*6 78H .2%G#71$.] Q"?2##0 (N's* J2.2 `$G8H2#2T712H /8 1-/0 ?$-$.1e

r 41/MG#71$.] Q"?2## 0/%871G.20 J2.2 -/%- /8 7)).$f/M712#] -7#` $` 1-2)$)G#71/$8 /8?#GH/8% Q-; (I@s*6 2``2?1$."M2M$.] (I@s*6 `$##/?G#7. -2#)2.(I&s*6 Q-& (E&s*6 78H b7MM7"H2#17 Q"?2##0 (@Ps*e

r C-/#2 ?]1$1$f/? ,9Ot Q"?2## 0/%871G.2 J70 -/%- /8 $8#] &Ps $` )71/28106 1-20/%871G.2 `$. 1-2 ,9IKH/M ?]1$#]1/? 0GD021 $` ZB ?2##0 J70 -/%- /8 EOs $`)71/2810e

r Q-2 M$01 /8`.2kG281#] H212?12H %282 0/%871G.20 J2.2 `$. /88712 .20)$802?2##"1])20i S701 ?2##0 (Os*6 S7?.$)-7%20 (&&s*6 /MM71G.2 H28H./1/? ?2##0(&&s* 78H 82G1.$)-/#0 (&;s*e

r &K 0/%871G.20 J2.2 0/%8/`/?781#] H/``2.281/7##] 7?1/T712H /8 QZA, ?$M)7.2H1$ -$.M$82".2?2)1$. )$0/1/T2 (RUt* )71/2810 ()p'e'I .20)2?1/T2#]*i! KgP 0/%871G.20 M$.2 7?1/T2 /8 QZA, 7.2 700$?/712H J/1- 7H7)1/T2/MMG82 .20)$802 (2e%e Q"?2## 78H A"?2## 0/%871G.20*m

! EgN 0/%871G.20 700$?/712H J/1- RUt 7.2 .2#712H 1$ /88712 /MMG82.20)$802 (2e%e 2$0/8$)-/#0 78H H28H./1/? ?2##0*e

r L#2T712H ZB ,9IKH/M6 Q-&6 78H 7?1/T712H H28H./1/? ?2## (79,*6 0/%871G.20J2.2 700$?/712H J/1- %.7H2 @ 1GM$.0 70 J2## 70 J/1- 2#2T712H #2T2#0 $` B/KN()p'e'''& .20)2?1/T2#]*e

r Q-2 M$01 ).2H/?1/T2 QSL 0/%871G.2 `$. )7?#/17f2#"D702H 1-2.7)] J70 Q`$##/?G#7. -2#)2. ?2##0 (Q>R*e

Coho

rtpr

opor

tion (

%)

High activity Normal activity Low activity

279 Geparsepto HER2-negative samples

1467

clini

cal c

ases

1467 reference clinical cases

>1200 example later-stage test cases

[Breast n=213]

Other

Breast

oo o ooo ooo oo

Mean

gene

set

expr

essio

nInf

erre

d ac

tivity

scor

e

!")$%%& '")$%%& 78")$%%& 4$D6,<=<)")$%%& ?.@/ G,>DA%B)E=$&H6>+=<I$"<33AD$",$&+BD&$ JDD>=$"<33AD$",$&+BD&$

K=-$, #E=B=BF<)")$%%& K=-$,

Positive correlationNegative correlation

(5:.K%&$%&'/

@

K%'1"5.RF..W881&5./36"5/.%&.0;5.!54#"P5406 36;6"0

&'E3%2820

_MMG823?2##3?712%$./20